ArticleBMC molecular and cell biology2026
Effects of irisin on inflammatory and apoptotic markers in the Caco-2 colon cancer cell line.
Article in BMC molecular and cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveIrisin is a myokine that is secreted by muscle tissue and is recognized for its regulatory effects on inflammation. The objective of this study was to examine the potential anti-inflammatory function of irisin in the context of colon cancer, with a focus on its effects on the Caco-2 cell line. Method: Specifically, pro-inflammatory cytokine levels (IL-6 and TNF-α), apoptotic marker Caspase-3 activity, and changes in the NF-κB signaling pathway were assessed using ELISA assays.
resultsThe findings of this study indicated a substantial augmentation in IL-6 levels in the 100 nM irisin-treated group in comparison to the control group (p < 0.05). Furthermore, a significant divergence in Caspase-3 activity was observed between the 10 nM and 100 nM irisin groups (p < 0.05). While direct antiproliferative effects of irisin on Caco-2 cells were not evident in analyses of cellular toxicity, a significant increase in Caspase-3 activity suggested activation of apoptotic pathways. Furthermore, the upregulation of NF-κB signaling, which is generally linked to cancer progression through the suppression of apoptosis, was observed following irisin treatment.
conclusionIrisin did not exert a consistent antiproliferative effect in Caco-2 cells under the tested conditions. Instead, irisin exposure was associated with alterations in inflammatory and apoptotic markers, including increased IL-6 and NF-κB levels and modulation of caspase-3 activity. These findings suggest that irisin may act as a context-dependent regulator of inflammatory and apoptotic signaling rather than a direct anti-inflammatory or antiproliferative agent in colon cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.